Paxil Special Report I Court Filing Makes Public My Previously Suppressed Analysis of Paxil's Effects
Peter R. Breggin, MD
Published in Ethical Human Psychology and Psychiatry 8, 77-84, 2006
Product liability cases against drug companies like GlaxoSmithKline are often settled with an agreement that the potentially incriminating data found in the drug company files will be sealed or kept secret. In the case of Lacuzong v. GlaxoSmithKline, my report disclosed extensive manipulation of data concerning Paxil's adverse effects, including rates of suicidality, psychomotor agitation (akathisia), and over-stimulation.
In a subsequent lawsuit against the company, my report was unsealed and is now available to the public. I placed the entire report on my website and published three scientific articles based on it. This is the first of the three articles.
As a medical expert, I was empowered by the court to examine hundreds of cartons of drug company files contained in GSK's sealed record room. These files included Food and Drug Administration (FDA) correspondence and all of the company's worldwide clinical trials and drug reports for Paxil.
Read complete article here
----
Paxil Special Report II How GlaxoSmithKline Suppressed Data on Paxil-Induced Akathisia: Implications for Suicidality and Violence
Peter R. Breggin, MD
Published in Ethical Human Psychology and Psychiatry 8, 91-100, 2006
Since the publication of my first special report concerning how the manufacturer of Paxil hid and manipulated data concerning Paxil-induced suicide, in May 2006 the drug company GlaxoSmithKline issued a letter to Healthcare Providers confirming that depressed adults of all ages taking the antidepressant have an increased rate of suicidality compared to depressed adults taking placebo. This special report is the second in a series demonstrating that GlaxoSmithKline hid or manipulated data that years ago indicated that Paxil increases the risk of suicidality and other dangerous adverse mental effects of the drug.Read complete article here
----
Paxil Special Report III Drug Company Suppressed Data on Paroxetine-Induced Stimulation: Implications for Violence and Suicide
Peter R. Breggin, MD
Published in Ethical Human Psychology and Psychiatry 8, 255-263, 2006
This third report focuses on the role of Paxil-induced central nervous system stimulation in causing violence and suicide and the manner in which GSK obscured or disguised the antidepressant's stimulating effects. Akathisia can be viewed as a form of central nervous system stimulation, and therefore this current report dovetails with the second report.
Read complete article here
No comments: